| # | Drug | Count |
|---|---|---|
| 0 | MACITENTAN | 917 |
| 1 | VENETOCLAX | 876 |
| 2 | FUROSEMIDE | 820 |
| 3 | ECULIZUMAB | 709 |
| 4 | SILDENAFIL CITRATE | 598 |
| 5 | BOSENTAN | 539 |
| 6 | ASPIRIN | 509 |
| 7 | TADALAFIL | 491 |
| 8 | ASPIRIN 325 MG | 477 |
| 9 | ASPIRIN 81 MG | 477 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | CEDAZURIDINE AND DECITABINE | 71 | 0.0725 |
| 1 | OLUTASIDENIB | 13 | 0.0450 |
| 2 | PACRITINIB | 84 | 0.0274 |
| 3 | REVUMENIB | 20 | 0.0194 |
| 4 | ALENDRONATE SODIUM AND CHOLECALCIFEROL | 49 | 0.0177 |
| 5 | EPOPROSTENOL | 193 | 0.0147 |
| 6 | PENTAMIDINE ISETHIONATE | 18 | 0.0143 |
| 7 | VENETOCLAX | 876 | 0.0139 |
| 8 | MACITENTAN | 917 | 0.0131 |
| 9 | ECULIZUMAB | 709 | 0.0130 |
| # | Drug class | Count |
|---|---|---|
| 0 | Endothelin Receptor Antagonist [EPC] | 1352 |
| 1 | Factor Xa Inhibitor [EPC] | 1065 |
| 2 | Nonsteroidal Anti-inflammatory Drug [EPC] | 940 |
| 3 | Loop Diuretic [EPC] | 939 |
| 4 | BCL-2 Inhibitor [EPC] | 876 |
| 5 | Corticosteroid [EPC] | 829 |
| 6 | Phosphodiesterase 5 Inhibitor [EPC] | 755 |
| 7 | Complement Inhibitor [EPC] | 742 |
| 8 | Kinase Inhibitor [EPC] | 655 |
| 9 | Platelet Aggregation Inhibitor [EPC] | 524 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 16 | 0.0233 |
| 1 | BCL-2 Inhibitor [EPC] | 876 | 0.0139 |
| 2 | Complement Inhibitor [EPC] | 742 | 0.0132 |
| 3 | Prostacyclin Receptor Agonist [EPC] | 329 | 0.0126 |
| 4 | Provitamin D2 Compound [EPC] | 358 | 0.0120 |
| 5 | CD38-directed Cytolytic Antibody [EPC] | 56 | 0.0096 |
| 6 | Soluble Guanylate Cyclase Stimulator [EPC] | 280 | 0.0083 |
| 7 | Complement C5 Inhibitor [EPC] | 1 | 0.0083 |
| 8 | Endothelin Receptor Antagonist [EPC] | 1352 | 0.0067 |
| 9 | Cytomegalovirus DNA Terminase Complex Inhibitor [EPC] | 20 | 0.0061 |